title: C75 alters central and peripheral gene expression to reduce food intake and increase energy expenditure.
abstract: C75, a synthetic inhibitor of fatty acid synthase (FAS), causes anorexia and profound weight loss in lean and genetically obese mice. C75 also acts as a stimulator of carnitine palmitoyltransferase-1 to induce fatty acid oxidation. To approximate human obesity, we used a 2-wk C75 treatment model for diet-induced obese (DIO) mice to investigate the central and peripheral effects of C75 on gene expression. C75 treatment decreased food intake, increased energy expenditure, and reduced body weight more effectively in DIO than in lean mice. Analysis of the gene expression changes in hypothalamus demonstrated that the reduced food intake in C75-treated DIO mice might be mediated by inhibition of orexigenic neuropeptide expression and induction of anorexigenic neuropeptide expression. Gene expression changes in peripheral tissues indicated that C75 increased energy expenditure by the induction of genes involved in fatty acid oxidation. C75 also inhibited the expression of genes in peripheral tissues responsible for fatty acid synthesis and accumulation. The patterns of the changes in central and peripheral gene expression that occur with C75 treatment provide mechanisms to explain the reduced food intake and increased energy expenditure observed with C75.
authors.affiliation: Department of Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
authors.forename: Yajun
authors.initials: Y
authors.lastname: Tu
authors.forename: Jagan N
authors.initials: JN
authors.lastname: Thupari
authors.forename: Eun-Kyoung
authors.initials: EK
authors.lastname: Kim
authors.forename: Michael L
authors.initials: ML
authors.lastname: Pinn
authors.forename: Timothy H
authors.initials: TH
authors.lastname: Moran
authors.forename: Gabriele V
authors.initials: GV
authors.lastname: Ronnett
authors.forename: Francis P
authors.initials: FP
authors.lastname: Kuhajda
mesh_terms: D015107:4-Butyrolactone / Q000031:analogs & derivatives* / Q000494:pharmacology*; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D004032:Diet; D004435:Eating / Q000187:drug effects* / Q000235:genetics; D004734:Energy Metabolism / Q000187:drug effects* / Q000235:genetics; D064429:Fatty Acid Synthases / Q000037:antagonists & inhibitors; D005227:Fatty Acids / Q000378:metabolism; D015870:Gene Expression / Q000187:drug effects*; D007031:Hypothalamus / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009479:Neuropeptides / Q000235:genetics / Q000378:metabolism; D009765:Obesity / Q000209:etiology / Q000235:genetics* / Q000473:pathology / Q000503:physiopathology; D010084:Oxidation-Reduction / Q000187:drug effects; D013851:Thinness / Q000235:genetics / Q000378:metabolism / Q000473:pathology
chemical_list: C406734:4-methylene-2-octyl-5-oxofuran-3-carboxylic acid; D005227:Fatty Acids; D009479:Neuropeptides; D064429:Fatty Acid Synthases; D015107:4-Butyrolactone